Antibodies

25 Jul 2017 Merck Provides Update on Phase 3 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
25 Jul 2017 UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis
24 Jul 2017 Seattle Genetics Announces Clinical Collaboration to Expand the Therapeutic Evaluation of SGN-LIV1A in Triple Negative Breast Cancer
24 Jul 2017 Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin®1 (bevacizumab
24 Jul 2017 U.S. Food and Drug Administration Expands Approval of Yervoy® (ipilimumab) to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
24 Jul 2017 Samsung Bioepis Announces RENFLEXIS™ (infliximab-abda) Now Available in the United States
22 Jul 2017 GSK receives FDA approval for a new self-injectable formulation of Benlysta (belimumab) for systemic lupus erythematosus
22 Jul 2017 EMA’s CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
22 Jul 2017 European Medicines Agency’s CHMP Recommends Approval for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
22 Jul 2017 Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
22 Jul 2017 AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis
22 Jul 2017 Phase II Trial of Investigational Anetumab Ravtansine Does Not Meet Primary Endpoint in Second-Line Mesothelioma
21 Jul 2017 FDA Accepts Biologics License Application For Aimovig™ (erenumab)
21 Jul 2017 Chugai Files a New Drug Application for Its Bispecific Monoclonal Antibody “Emicizumab” for the Treatment of Congenital Factor VIII Deficiency (Hemophilia A) with Factor VIII Inhibitors
21 Jul 2017 Bimekizumab Demonstrates Skin Clearance in Phase 2b Psoriasis Study with first monoclonal antibody neutralizing both IL-17A and IL-17F
20 Jul 2017 Emergent BioSolutions to Acquire Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
20 Jul 2017 Kyntheum approved in the EU for the treatment of adults with moderate-to-severe plaque psoriasis
19 Jul 2017 FDA Accepts CSL Behring's Supplemental Biologics License Application for Hizentra® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication
19 Jul 2017 OSE Immunotherapeutics Receives €9.2 million Grant from Bpifrance “Invest in the Future Program” for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM)
18 Jul 2017 Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development
17 Jul 2017 New Evidence of Sutro ADC's Potency in Human Tumor Xenografts
17 Jul 2017 China's First Fully Human, Full-length Anti-PD-L1 Monoclonal Antibody Receives Approval to Initiate Clinical Trials by the China Food and Drug Administration
17 Jul 2017 Apexigen, Inc. Announces First Patient Dosed in Phase 1b/2 Clinical Trial of APX005M in Combination with Opdivo (nivolumab) in Advanced Solid Tumors
17 Jul 2017 Amgen And UCB Provide Update On Regulatory Status Of EVENITY™ (romosozumab) In The US
14 Jul 2017 Janssen announces u.s. FDA approval of Tremfya™ (guselkumab) for the treatment of moderate to severe plaque psoriasis

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top